July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Noninfectious Inflammation after Intravitreal Aflibercept (EYLEA®) Injection for Patient with Exudative Age-related Macular Degeneration
Author Affiliations & Notes
  • Younghoon Lee
    ophthalmology, Konyang university hospital, Daejeon, Korea (the Republic of)
  • Byung Yi Ko
    ophthalmology, Konyang university hospital, Daejeon, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Younghoon Lee, None; Byung Yi Ko, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1443. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Younghoon Lee, Byung Yi Ko; Noninfectious Inflammation after Intravitreal Aflibercept (EYLEA®) Injection for Patient with Exudative Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1443.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the clinical features and outcome of noninfectious inflammation after intravitreal aflibercept injection

Methods : Retrospective medical records review of patients who presented with noninfectious inflammation after intravitreal aflibercept injection provide 1 clinician between January 1, 2015 and October 31, 2017

Results : The overall incidence of inflammation after intravitreal aflibercept injection was 12 of 839 injections (1.43%) or 8 of 241 patients (3.32%). The patients presented 1–7 days after aflibercept injection (median 3 days); 4 of 8 patients (50%) noted decreased vision and floater, otherwise 4 patients had no symptom. The average anterior chamber cell was 1.5+ (range 0.5+ to 3+) and all eyes had some degree of vitritis (average 1.0+; range 0 to 3+) according to the Standardization of Uveitis Nomenclature grading scheme. 4 patients were switched from ranibizumab(Lucentis®) and another 4 patients were started with aflibercept. Patients on average had received 0.87 prior aflibercept injections (range 0–3). All patients were managed with frequent topical and systemic steroids (prednisolone 20~30mg/day) and were followed closely for signs of improvement. All patients regained their preinjection visual acuity (average: 13 days; range: 7–21 days). And all patients were subsequently rechallenged with aflibercept. Topical and systemic steroids (prednisolone 20mg/day) for 3 days were used as the pretreatment to prevent inflammation after next aflibercept injection. Only 1 patient recurred 5 times. As the injection was repeated, the inflammation of the patient tended to decrease.

Conclusions : Noninfectious inflammation after intravitreal aflibercept injection typically presents with mild inflammatory sign and without pain. And it showed good responds to steroid therapy. Steroid pretreatment might play a role in preventing and reducing the recurrence of post-injection inflammation.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×